Navigation Links
Common virus may help doctors treat deadly brain tumors
Date:10/22/2007

DURHAM, N.C. -- A common human virus may prove useful in attacking the deadliest form of brain tumors, according to a study by researchers at Dukes Preston Robert Tisch Brain Tumor Center. The researchers said the finding is an important step in developing a vaccine that can attack the tumors by enlisting the help of the bodys immune system.

Human cytomegalovirus (HCMV), which infects 50 percent to 90 percent of people at some point during their lives, is active in more than 90 percent of patients diagnosed with glioblastoma multiforme, the most deadly type of malignant brain tumor, said Duane Mitchell, M.D., Ph.D., a brain cancer researcher and lead investigator on the study.

We dont know if the virus plays a part in the growth of the brain tumors or whether the presence of the brain tumors leads to a reactivation of the virus, Mitchell said. But we do know that the virus has the potential to affect the growth and invasiveness of cancer cells. So if we can target it, we may be able to empower the bodys immune system to fight infected tumor cells and destroy the cancer.

According to the researchers, a vaccine targeting HCMV likely would be administered to patients following conventional chemotherapy. The immune systems recovery from chemotherapy is marked by a regenerative burst of new immune cells, and the vaccine would take advantage of this reaction to effect an even stronger immune response to the virus, Mitchell said.

The researchers will publish their findings in the February 2008 print issue of the journal Neuro-Oncology. The study was published early online on October 19, 2007. The research was funded by the National Institutes of Health, The Brain Tumor Society and Accelerate Brain Cancer Cure, a not-for-profit organization that supports research to hasten a cure for brain cancer.

In healthy people with fully functional immune systems, the initial HCMV infection can be symptom-free or it can be associated with mild flulike symptoms. After infection, the virus becomes dormant and stays that way for the life of the infected person. But in people with weakened immune systems -- such as AIDS patients or those undergoing bone marrow transplant -- HCMV can become reactivated and cause more severe illnesses, such as pneumonia.

HCMVs association with brain tumors was first demonstrated in 2002 by researchers at the University of Alabama - Birmingham, but their results had not been repeated despite several attempts.

We not only confirmed the virus association with the tumors but also saw that patients with glioblastoma multiforme had detectable virus in their bloodstreams, where the comparative group did not, Mitchell said. This association may help us assess the success of vaccine treatment, since we will be better able to monitor response in patients, even after their tumors have been removed.

Based on the results of this study, Duke researchers have developed a vaccine that targets HCMV and are conducting a clinical trial to assess the vaccines safety and its effectiveness at building immunity to HCMV in patients with brain tumors. In the trial, which will complete enrollment this year, the vaccine is given monthly to cancer patients in conjunction with chemotherapy for as long as their tumors remain stable.

Were encouraged by the early results were seeing in the clinical trial and were pleased that the initial study enabled us to proceed with testing this vaccine in patients, Mitchell said. Because HCMV is present in such a large number of glioblastoma multiforme patients, the development of an effective treatment that targets the virus could have significant implications for this deadly disease.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Iron supplementation for a common side effect
3. Genetic Breakthrough in Common Eye Problem
4. Common Cold Found to Fight Cancer Cells
5. Side Effects Of Some Common Drugs
6. E. coli strains resistant to a common antibiotic
7. Gastrointestinal ills more common in diabetics
8. Toxic effects common with AIDS treatments
9. Common contraception
10. Drooping eyelids more common in men
11. Unnatural death common in mentally ill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: